Asieris Pharmaceuticals to Participate at CBIIC

Shanghai, China, September 18, 2019 – Asieris Pharmaceuticals, a clinical-stage biopharmaceutical company, announced today that Dr. Kevin Pan, the company CEO, will participate at China BioMed Innovation and Investment Conference (CBIIC) being held on Sep 21 – 23, 2019, in Suzhou, China. Dr. Pan will make a speech with the title of “APL-1202, the 1st Oral Therapy for Non-Muscle Invasive Bladder Cancer: Phase 2 Clinical Trial Results and Updates of the Pivotal ACCURE-1 Study”.

CBIIC was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. As an annual grand conference to promote the communication between pharmaceutical industry and investment industry, CBIIC aims to integrate the power of pharmaceutical innovation and investment at home and abroad to build an authorized, comprehensive, professional and international high level platform where the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors can learn the trend of innovation, seek high value projects and discuss new investment channels and innovative cooperation strategies to facilitate the timely transformation of unmet clinical needs and promote the pharmaceutical innovation serve the public health.